IMMUNITYBIO, INC. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
IMMUNITYBIO, INC. (IBRX) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $2.88 million for the 12-month period ending 2020-12-31, per its 8-K/A filed 2021-04-22.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2021-04-22
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|
| 2020-12-31 | $2.88M 8-K/A · filed 2021-04-22 |
| 2019-12-31 | -$320.00K 8-K/A · filed 2021-04-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |